International journal of radiation oncology, biology, physics

publication venue for

Immune Response following FLASH and Conventional Radiation in Diffuse Midline Glioma (DMG). 2024
Cardiorespiratory Fitness in Patients With Early-Stage Breast Cancer and Radiation Therapy-Related Fatigue: A Prospective Pilot Study.. 118. 2023
A Prospective Registry Study of ⁶⁸Ga-DOTATATE PET/CT Incorporation into Treatment Planning of Intracranial Meningiomas. 2023
A Phase II Trial Evaluating Rapid Mid-Treatment Nodal Shrinkage to Select for Adaptive Deescalation in p16+ Oropharyngeal Cancer Patients Undergoing Definitive Chemoradiation.. 117. 2023
Progression-Free Survival in Patients with WHO-2 Meningioma Undergoing Active Surveillance Based on DOTATATE PET Evidence of Gross Total Resection: Prospective Observational Study.. 117. 2023
Randomized Trial of Five or Two MRI-guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT).. 117. 2023
Retinopathy, Optic Neuropathy, and Cataract in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. 2023
ACTIVATION OF STING IN RESPONSE TO PARTIAL-TUMOR RADIATION EXPOSURE: STING ACTIVATION IN RESPONSE TO RADIATION EXPOSURE. 2023
A Multi-Institutional Phase II Trial of Ablative 5-Fraction Stereotactic MR-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. 2023
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.. 116. 2023
Radiation Oncology residency training program integration of diversity, equity, and inclusion: An Association of Residents in Radiation Oncology Equity and Inclusion Subcommittee (ARRO EISC) inaugural program director survey. 2023
A Multicenter Prospective Trial of Electronic Skin Surface Brachytherapy for Keratinocyte Carcinoma: Early Cosmesis, Quality of Life, and Adverse Events.. 116. 2022
Radiation Oncology resident perspectives on diversity, equity, and inclusion: an Association of Residents in Radiation Oncology Equity and Inclusion Subcommittee (ARRO EISC) inaugural resident survey. 2022
Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer.. 114. 2022
Radiation Oncology AcaDemic Mentorship Program (ROADMAP) for Junior Faculty: 1-Year Results of a Prospective Single Institution Initiative. 2022
A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. 2022
Responses to the 2018 and 2019 "One Big Discovery" Question: ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology…Where Are We Headed?. 109. 2020
Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.. 110. 2020
Identification of Radioresponsive Genes in Esophageal Cancer from Longitudinal and Single Cell Exome Sequencing.. 108. 2020
High-Dose Radiation Increases Notch1 in Tumor Vasculature.. 106. 2019
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.. 106. 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.. 104. 2019
Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.. 104. 2019
Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio.. 103. 2019
Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st Century.. 104. 2019
An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models.. 103. 2018
Responses to the 2017 "1 Million Gray Question": ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology.. 102. 2018
Combination Therapy of Intravenously Injected Microglia and Radiation Therapy Prolongs Survival in a Rat Model of Spontaneous Malignant Glioma.. 102. 2018
Hypofractionated Whole-Breast Irradiation in Women Less Than 50 Years Old Treated on 4 Prospective Protocols.. 101. 2018
Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.. 101. 2018
Theragnostic Target, Prostate-Specific Membrane Antigen-Also Specific for Nonprostatic Malignancies.. 101. 2018
Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation.. 101. 2018
Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations.. 101. 2018
Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?. 100. 2018
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.. 100. 2017
Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).. 99. 2017
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.. 99. 2017
Clinical Outcomes of Large Brain Metastases Treated With Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective Trial.. 98. 2017
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.. 98. 2017
Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.. 98. 2017
External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.. 98. 2017
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.. 98. 2017
Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.. 97. 2017
Use of Geriatric Assessment Tools in Selecting Therapies in Women Aged ≥70 Years With Hormone Receptor-Positive Early-Stage Breast Cancer: Preliminary Experience With a Quality Improvement Initiative.. 98. 2017
Pan-Cancer Analysis of Genomic Sequencing Among the Elderly.. 98. 2017
Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.. 97. 2016
Morphologic Features of Magnetic Resonance Imaging as a Surrogate of Capsular Contracture in Breast Cancer Patients With Implant-based Reconstructions.. 97. 2016
Initial Report on Safety and Lesion Response of Melanoma Brain Metastases After Stereotactic Radiosurgery or Hypofractionated Radiation Therapy in Patients Receiving Concurrent Pembrolizumab.. 96. 2016
Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.. 97. 2016
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.. 97. 2016
Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model.. 96. 2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.. 96. 2016
Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.. 96. 2016
Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer.. 96. 2016
Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.. 96. 2016
Long-Term Cancer Outcomes From Study NRG Oncology/RTOG 9517: A Phase 2 Study of Accelerated Partial Breast Irradiation With Multicatheter Brachytherapy After Lumpectomy for Early-Stage Breast Cancer.. 95. 2016
Radiation-Induced Esophagitis In Vivo and In Vitro Reveals That Epidermal Growth Factor Is a Potential Candidate for Therapeutic Intervention Strategy.. 95. 2016
Real-time Tumor Oxygenation Changes After Single High-dose Radiation Therapy in Orthotopic and Subcutaneous Lung Cancer in Mice: Clinical Implication for Stereotactic Ablative Radiation Therapy Schedule Optimization.. 95. 2016
Quality of Life in Women Undergoing Breast Irradiation in a Randomized, Controlled Clinical Trial Evaluating Different Tumor Bed Boost Fractionations.. 95. 2016
Comparison of Mammographic Changes Across Three Different Fractionation Schedules for Early-Stage Breast Cancer.. 95. 2016
Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer.. 95. 2016
High-Dose, Single-Fraction Irradiation Rapidly Reduces Tumor Vasculature and Perfusion in a Xenograft Model of Neuroblastoma.. 94. 2015
Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed.. 95. 2015
Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy for Rectal Cancer.. 94. 2015
Kilovoltage Imaging of Implanted Fiducials to Monitor Intrafraction Motion With Abdominal Compression During Stereotactic Body Radiation Therapy for Gastrointestinal Tumors.. 95. 2015
The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study.. 94. 2015
Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial.. 94. 2015
Concomitant Imaging Dose and Cancer Risk in Image Guided Thoracic Radiation Therapy.. 93. 2015
Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models.. 93. 2015
Five-Year Outcomes of High-Dose Single-Fraction Spinal Stereotactic Radiosurgery.. 93. 2015
Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent.. 92. 2015
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.. 92. 2015
Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.. 92. 2015
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.. 92. 2015
Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy.. 91. 2015
Modeling pancreatic tumor motion using 4-dimensional computed tomography and surrogate markers.. 91. 2015
Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature.. 91. 2014
Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography.. 90. 2014
Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.. 90. 2014
Outcomes and prognostic factors in women with 1 to 3 breast cancer brain metastases treated with definitive stereotactic radiosurgery.. 90. 2014
Prone breast intensity modulated radiation therapy: 5-year results.. 89. 2014
Refusal of curative radiation therapy and surgery among patients with cancer.. 89. 2014
A prospective study of ¹⁸FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies.. 89. 2014
Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.. 89. 2014
Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine.. 88. 2014
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.. 89. 2014
Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer.. 88. 2014
32P brachytherapy conformal source model RIC-100 for high-dose-rate treatment of superficial disease: Monte Carlo calculations, diode measurements, and clinical implementation.. 88. 2014
Performance of a nomogram predicting disease-specific survival after an R0 resection for gastric cancer in patients receiving postoperative chemoradiation therapy.. 88. 2014
A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases.. 88. 2014
Administration of concurrent vaginal brachytherapy during chemotherapy for treatment of endometrial cancer.. 87. 2013
Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary.. 88. 2013
A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.. 87. 2013
Burnout in United States academic chairs of radiation oncology programs.. 88. 2013
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.. 87. 2013
Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.. 87. 2013
Changes in bone mineral density in uterine cervical cancer patients after radiation therapy.. 87. 2013
Transforming growth factor β-1 (TGF-β1) is a serum biomarker of radiation induced fibrosis in patients treated with intracavitary accelerated partial breast irradiation: preliminary results of a prospective study.. 87. 2013
Salvage/adjuvant brachytherapy after ophthalmic artery chemosurgery for intraocular retinoblastoma.. 87. 2013
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.. 86. 2013
Late toxicity and patient self-assessment of breast appearance/satisfaction on RTOG 0319: a phase 2 trial of 3-dimensional conformal radiation therapy-accelerated partial breast irradiation following lumpectomy for stages I and II breast cancer.. 86. 2013
Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study.. 86. 2013
Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.. 86. 2013
Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.. 86. 2013
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.. 86. 2013
Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols.. 86. 2013
Early-stage breast cancer treated with 3-week accelerated whole-breast radiation therapy and concomitant boost.. 86. 2013
Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers.. 86. 2012
Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.. 85. 2012
Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience.. 85. 2012
Parameningeal rhabdomyosarcoma: outcomes and opportunities.. 85. 2012
Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.. 85. 2012
The role of postoperative radiation therapy in the treatment of meningeal hemangiopericytoma-experience from the SEER database.. 85. 2012
Fractures of the sacrum after chemoradiation for rectal carcinoma: incidence, risk factors, and radiographic evaluation.. 84. 2012
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.. 85. 2012
Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.. 85. 2012
Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.. 84. 2012
Evaluation of rotational errors in treatment setup of stereotactic body radiation therapy of liver cancer.. 84. 2012
Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.. 83. 2012
Intensity modulated radiation therapy with dose painting to treat rhabdomyosarcoma.. 84. 2012
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.. 83. 2012
Identification and characterization of a small inhibitory peptide that can target DNA-PKcs autophosphorylation and increase tumor radiosensitivity.. 84. 2012
Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer.. 84. 2012
Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy.. 84. 2012
Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery.. 83. 2012
Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma.. 84. 2012
Quantifying the impact of immediate reconstruction in postmastectomy radiation: a large, dose-volume histogram-based analysis.. 84. 2012
Adjuvant radiation therapy and survival for pure tubular breast carcinoma--experience from the SEER database.. 84. 2012
Prone accelerated partial breast irradiation after breast-conserving surgery: compliance to the dosimetry requirements of RTOG-0413.. 84. 2012
Prone accelerated partial breast irradiation after breast-conserving surgery: five-year results of 100 patients.. 84. 2012
Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients.. 84. 2012
Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy.. 84. 2012
Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.. 84. 2012
Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.. 84. 2012
Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.. 84. 2012
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.. 83. 2012
Predicting the risk of secondary lung malignancies associated with whole-breast radiation therapy.. 83. 2012
Effects of irradiation on brain vasculature using an in situ tumor model.. 82. 2011
Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.. 83. 2011
Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination.. 83. 2011
Delayed radiation-induced vasculitic leukoencephalopathy.. 83. 2011
Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique.. 82. 2011
Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients.. 82. 2011
Radiation therapy for chloroma (granulocytic sarcoma).. 82. 2011
Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer.. 82. 2011
Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer.. 81. 2011
Patterns of utilization of adjuvant radiotherapy and outcomes in black women after breast conservation at a large multidisciplinary cancer center.. 80. 2011
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.. 82. 2011
Stereotactic body radiotherapy for primary hepatocellular carcinoma.. 81. 2011
Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes.. 82. 2011
Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases.. 82. 2011
Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma.. 82. 2011
Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer.. 81. 2011
Prospective study of cone-beam computed tomography image-guided radiotherapy for prone accelerated partial breast irradiation.. 81. 2011
MicroRNA-221 and -222 regulate radiation sensitivity by targeting the PTEN pathway.. 80. 2011
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.. 82. 2011
Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.. 81. 2011
Coordination of breast cancer care between radiation oncologists and surgeons: a survey study.. 82. 2011
Choreographing couch and collimator in volumetric modulated arc therapy.. 80. 2011
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.. 82. 2011
Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver.. 80. 2011
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.. 82. 2011
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience.. 82. 2010
Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.. 82. 2010
Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.. 81. 2010
Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.. 81. 2010
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.. 81. 2010
Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?. 81. 2010
[¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.. 81. 2010
Impact of dose on local failure rates after image-guided reirradiation of recurrent paraspinal metastases.. 81. 2010
Incidence and treatment patterns in hospitalizations for malignant spinal cord compression in the United States, 1998-2006.. 80. 2010
Response to multiple radiation doses of human colorectal carcinoma cells infected with recombinant adenovirus containing dominant-negative Ku70 fragment.. 77. 2010
Proteomic analysis of radiation-induced changes in rat lung: Modulation by the superoxide dismutase mimetic MnTE-2-PyP(5+).. 78. 2010
Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy.. 79. 2010
Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial.. 80. 2010
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size.. 79. 2010
Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases.. 79. 2010
Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.. 79. 2010
Improved dosimetric and clinical outcomes with intensity-modulated radiotherapy for head-and-neck cancer of unknown primary origin.. 79. 2010
Melanin-covered nanoparticles for protection of bone marrow during radiation therapy of cancer.. 78. 2010
Prospective study validating inter- and intraobserver variability of tissue compliance meter in breast tissue of healthy volunteers: potential implications for patients with radiation-induced fibrosis of the breast.. 80. 2010
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.. 78. 2010
Correlation of local failure with measures of dose insufficiency in the high-dose single-fraction treatment of bony metastases.. 77. 2010
Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.. 78. 2010
Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.. 78. 2010
Imaging primary lung cancers in mice to study radiation biology.. 76. 2010
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma.. 78. 2010
Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions.. 76. 2010
Optimization of collimator trajectory in volumetric modulated arc therapy: development and evaluation for paraspinal SBRT.. 77. 2010
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.. 78. 2010
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.. 76. 2010
Toxicity of head-and-neck radiation therapy in human immunodeficiency virus-positive patients.. 77. 2010
Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy.. 76. 2010
Decreasing temporal lobe dose with five-field intensity-modulated radiotherapy for treatment of pituitary macroadenomas.. 78. 2009
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.. 77. 2009
Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/ II breast carcinoma.. 77. 2009
Interfraction and intrafraction setup variability for prone breast radiation therapy.. 76. 2009
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.. 77. 2009
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.. 77. 2009
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.. 76. 2009
Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment.. 74. 2009
High-dose-rate intraoperative radiation therapy for recurrent head-and-neck cancer.. 76. 2009
Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable.. 76. 2009
Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases.. 76. 2009
Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.. 75. 2009
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.. 74. 2009
Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study.. 75. 2009
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.. 75. 2009
Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX).. 74. 2009
Phase I trial of vertebral intracavitary cement and samarium (VICS): novel technique for treatment of painful vertebral metastasis.. 75. 2009
Immunohistochemical detection of changes in tumor hypoxia.. 73. 2009
Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience.. 73. 2009
Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.. 75. 2009
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.. 75. 2009
The value of the internship for radiation oncology training: results of a survey of current and recent trainees.. 74. 2009
Accelerated whole breast irradiation with intensity-modulated radiotherapy to the prone breast.. 73. 2009
Radiosensitization by inhibiting STAT1 in renal cell carcinoma.. 73. 2009
Reproducibility of interfraction lung motion probability distribution function using dynamic MRI: statistical analysis.. 72. 2008
External validation of the updated partin tables in a cohort of French and Italian men.. 73. 2008
Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging.. 74. 2008
Multi-institutional external validation of seminal vesicle invasion nomograms: head-to-head comparison of Gallina nomogram versus 2007 Partin tables.. 73. 2008
Commissioning and quality assurance of RapidArc radiotherapy delivery system.. 72. 2008
Postmastectomy chest wall radiation to a temporary tissue expander or permanent breast implant--is there a difference in complication rates?. 74. 2008
Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.. 73. 2008
Coverage of axillary lymph nodes in supine vs. prone breast radiotherapy.. 73. 2008
Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors.. 71. 2008
Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.. 73. 2008
Comparison of kilovoltage cone-beam computed tomography with megavoltage projection pairs for paraspinal radiosurgery patient alignment and position verification.. 71. 2008
Clinical outcomes of postmastectomy radiation therapy after immediate breast reconstruction.. 72. 2008
Local control after intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma.. 73. 2008
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.. 72. 2008
Response to multiple radiation doses of fibroblasts over-expressing dominant negative Ku70.. 71. 2008
Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities.. 72. 2008
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.. 72. 2008
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.. 70. 2008
The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.. 70. 2008
A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17.. 72. 2008
Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.. 71. 2008
Intensity-modulated radiation therapy in childhood ependymoma.. 71. 2008
High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions.. 71. 2008
Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa.. 70. 2008
IMRT delivery performance with a varian multileaf collimator.. 71. 2008
Quality assurance challenges for motion-adaptive radiation therapy: gating, breath holding, and four-dimensional computed tomography.. 71. 2008
Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.. 70. 2008
A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).. 71. 2007
Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118.. 71. 2007
Supine craniospinal irradiation using intrafractional junction shifts and field-in-field dose shaping: early experience at Methodist Hospital.. 71. 2007
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.. 71. 2007
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.. 70. 2007
Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience.. 70. 2007
Quantitative assessment of range fluctuations in charged particle lung irradiation.. 70. 2007
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.. 70. 2007
Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer.. 70. 2007
Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes.. 70. 2007
Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence.. 69. 2007
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.. 69. 2007
Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer.. 69. 2007
Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.. 69. 2007
Image-guided intensity-modulated photon radiotherapy using multifractionated regimen to paraspinal chordomas and rare sarcomas.. 69. 2007
Accelerated intensity-modulated radiotherapy to breast in prone position: dosimetric results.. 68. 2007
Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma.. 69. 2007
Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy.. 69. 2007
Dose as a function of lung volume and planned treatment volume in helical tomotherapy intensity-modulated radiation therapy-based stereotactic body radiation therapy for small lung tumors.. 68. 2007
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.. 69. 2007
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.. 69. 2007
Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer.. 69. 2007
Single-fraction intraoperative radiotherapy for breast cancer: early cosmetic results.. 69. 2007
Who enrolls onto clinical oncology trials? A radiation Patterns Of Care Study analysis.. 68. 2007
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.. 68. 2007
Observation of interfractional variations in lung tumor position using respiratory gated and ungated megavoltage cone-beam computed tomography.. 67. 2007
Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.. 68. 2007
Salvage re-irradiation for recurrent head and neck cancer.. 68. 2007
Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results.. 68. 2007
Long-term clinical outcomes of whole-breast irradiation delivered in the prone position.. 68. 2007
The impact of positron emission tomography/computed tomography in edge delineation of gross tumor volume for head and neck cancers.. 68. 2007
A dosimetric evaluation of conventional helmet field irradiation versus two-field intensity-modulated radiotherapy technique.. 68. 2007
Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.. 67. 2007
Surgical approaches to the oral cavity primary and neck.. 69. 2007
Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience.. 67. 2006
A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.. 66. 2006
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.. 67. 2006
Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer.. 66. 2006
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.. 66. 2006
Do metallic ports in tissue expanders affect postmastectomy radiation delivery?. 66. 2006
Genetic predictors of adverse radiotherapy effects: the Gene-PARE project.. 65. 2006
Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.. 65. 2006
Comparison of biochemical failure definitions for permanent prostate brachytherapy.. 65. 2006
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.. 65. 2006
A gradient feature weighted Minimax algorithm for registration of multiple portal images to 3DCT volumes in prostate radiotherapy.. 65. 2006
The vitamin-like dietary supplement para-aminobenzoic acid enhances the antitumor activity of ionizing radiation.. 65. 2006
Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.. 65. 2006
Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).. 65. 2006
The challenging role of radiation therapy for very young children with rhabdomyosarcoma.. 65. 2006
Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results.. 64. 2006
Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys.. 64. 2006
Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.. 65. 2006
ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy.. 64. 2005
Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).. 63. 2005
Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.. 63. 2005
A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319.. 63. 2005
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.. 64. 2005
Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era.. 64. 2005
Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer.. 63. 2005
Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity.. 63. 2005
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases.. 62. 2005
Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.. 62. 2005
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.. 63. 2005
Effects of motexafin gadolinium on DNA damage and X-ray-induced DNA damage repair, as assessed by the Comet assay.. 62. 2005
Intensity-modulated radiotherapy technique for three-field breast treatment.. 62. 2005
Radiation treatment planning techniques for lymphoma of the stomach.. 62. 2005
The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.. 63. 2005
Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons.. 63. 2005
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.. 63. 2005
Dependence of FDG uptake on tumor microenvironment.. 62. 2005
Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.. 62. 2005
Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.. 64. 2005
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.. 63. 2005
Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?. 62. 2005
Intensity-modulated radiotherapy for lymphoma involving the mediastinum.. 62. 2005
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.. 62. 2005
Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report.. 62. 2005
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.. 61. 2005
Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma.. 61. 2005
Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.. 61. 2005
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?. 61. 2005
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.. 61. 2005
Biologic comparison of partial breast irradiation protocols.. 60. 2004
Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas.. 60. 2004
Postmastectomy CT-based electron beam radiotherapy: dosimetry, efficacy, and toxicity in 118 patients.. 60. 2004
Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer.. 60. 2004
Measurement of lung tumor motion using respiration-correlated CT.. 60. 2004
Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning.. 60. 2004
Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis.. 60. 2004
Dosimetric analysis of a simplified intensity modulation technique for prone breast radiotherapy.. 60. 2004
Status of postmastectomy radiotherapy in the United States: a patterns of care study.. 60. 2004
Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.. 59. 2004
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.. 59. 2004
Long-term treatment results of invasive cervical cancer patients undergoing inadvertent hysterectomy followed by salvage radiotherapy.. 59. 2004
Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning.. 58. 2004
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.. 58. 2004
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.. 58. 2004
Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.. 58. 2004
Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.. 58. 2004
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.. 58. 2004
Comparison of an image registration technique based on normalized mutual information with a standard method utilizing implanted markers in the staged radiosurgical treatment of large arteriovenous malformations.. 57. 2003
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.. 57. 2003
The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us?. 57. 2003
Clinical implementation of an automated planning system for gamma knife radiosurgery.. 56. 2003
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.. 56. 2003
Radiosurgical treatment of trigeminal neuralgia: evaluating quality of life and treatment outcomes.. 56. 2003
Tolerance of tissue transfers to adjuvant radiation therapy in primary soft tissue sarcoma of the extremity.. 56. 2003
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.. 56. 2003
Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.. 56. 2003
The evolution of quality assurance for intensity- modulated radiation therapy (IMRT): sequential tomotherapy.. 56. 2003
Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.. 55. 2003
Evaluation of rapid dose map acquisition of a scanning liquid-filled ionization chamber electronic portal imaging device.. 55. 2003
Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.. 55. 2003
Role of IMRT in reducing penile doses in dose escalation for prostate cancer.. 55. 2003
CT image-guided intensity-modulated therapy for paraspinal tumors using stereotactic immobilization.. 55. 2003
Development of a semi-automatic alignment tool for accelerated localization of the prostate.. 55. 2003
Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer.. 55. 2003
Optimization of conformal thoracic radiotherapy using cone-beam CT imaging for treatment verification.. 55. 2003
Respiratory gating for liver tumors: use in dose escalation.. 55. 2003
Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis.. 54. 2002
Evaluation of concave dose distributions created using an inverse planning system.. 54. 2002
Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.. 54. 2002
IMRT of large fields: whole-abdomen irradiation.. 54. 2002
Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?. 54. 2002
Outcome of primary soft tissue sarcoma of the knee and elbow.. 54. 2002
Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function.. 54. 2002
Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumor.. 54. 2002
High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients.. 53. 2002
Intensity-modulated radiation therapy (IMRT) for meningioma.. 53. 2002
Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.. 53. 2002
Influence of radiation dose on positive surgical margins in women undergoing breast conservation therapy.. 53. 2002
Intensity-modulated radiotherapy versus conventional three-dimensional conformal radiotherapy for boost or salvage treatment of nasopharyngeal carcinoma.. 53. 2002
Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer.. 53. 2002
Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy.. 53. 2002
The Anderson nomograms for permanent interstitial prostate implants: a briefing for practitioners.. 53. 2002
Chromosomal aberrations induced by chemotherapy and radiotherapy in lymphocytes from patients with breast carcinoma.. 52. 2002
Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery.. 52. 2002
Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity.. 52. 2002
Evaluation of respiratory movement during gated radiotherapy using film and electronic portal imaging.. 52. 2002
Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer.. 52. 2002
Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer.. 52. 2002
Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.. 52. 2002
Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society.. 51. 2001
Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model.. 51. 2001
Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data.. 51. 2001
Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal.. 51. 2001
Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy.. 51. 2001
Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer.. 51. 2001
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report.. 51. 2001
Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens.. 51. 2001
T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.. 51. 2001
Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status.. 50. 2001
Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers.. 50. 2001
Room shielding for intensity-modulated radiation therapy treatment facilities.. 50. 2001
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.. 49. 2001
Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma.. 49. 2001
Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis.. 49. 2001
Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.. 49. 2001
Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer.. 49. 2001
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.. 49. 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Breast Cancer Working Group.. 51. 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee.. 51. 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gynecology Cancer Working Group.. 51. 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee.. 51. 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Tumor Utilization Committee.. 51. 2001
Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity.. 48. 2000
Technical aspects of the deep inspiration breath-hold technique in the treatment of thoracic cancer.. 48. 2000
Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection.. 48. 2000
Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome.. 48. 2000
Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique.. 48. 2000
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer.. 48. 2000
The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer.. 48. 2000
Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models.. 47. 2000
Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.. 47. 2000
Morbidity of adjuvant brachytherapy in soft tissue sarcoma of the extremity and superficial trunk.. 47. 2000
Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.. 47. 2000
Prone breast radiotherapy in early-stage breast cancer: a preliminary analysis.. 47. 2000
High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas.. 47. 2000
Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.. 47. 2000
Relative profile and dose verification of intensity-modulated radiation therapy.. 47. 2000
Brachytherapy radiation doses to the neurovascular bundles.. 46. 2000
Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.. 46. 2000
Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer.. 46. 2000
Local control with multimodality therapy for stage 4 neuroblastoma.. 46. 2000
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.. 45. 1999
In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.. 45. 1999
Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation.. 45. 1999
Dosimetric comparison of three photon radiosurgery techniques for an elongated ellipsoid target.. 45. 1999
Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer.. 45. 1999
Repair of DNA double-strand breaks and radiosensitivity to killing in an isogenic group of p53 mutant cell lines.. 45. 1999
Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy.. 45. 1999
Five year results of LINAC radiosurgery for arteriovenous malformations: outcome for large AVMS.. 44. 1999
Intensity-modulated tangential beam irradiation of the intact breast.. 44. 1999
Conservative management of rectal cancer with local excision and postoperative adjuvant therapy.. 44. 1999
Technology assessment of multileaf collimation: a North American users survey.. 44. 1999
Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.. 43. 1999
Radiosurgery for brain metastases: is whole brain radiotherapy necessary?. 43. 1999
Computerized design of target margins for treatment uncertainties in conformal radiotherapy.. 43. 1999
Prevalence of mood disorders and utility of the PRIME-MD in patients undergoing radiation therapy.. 42. 1998
High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer.. 42. 1998
Radiographic findings and morbidity in patients treated with stereotactic radiosurgery.. 42. 1998
Mathematical model of 5-[125I]iodo-2'-deoxyuridine treatment: continuous infusion regimens for hepatic metastases.. 41. 1998
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.. 41. 1998
A dose-response study for I-125 prostate implants.. 41. 1998
Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.. 40. 1998
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme.. 40. 1998
A feasibility study of automated inverse treatment planning for cancer of the prostate.. 40. 1998
Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.. 40. 1998
Electron wedges for radiation therapy.. 40. 1998
Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer.. 40. 1998
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.. 40. 1998
Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate.. 40. 1998
Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy.. 39. 1997
Radiation enhancement by biochemical modulation and 5-fluorouracil.. 39. 1997
Radiosensitivity of Koch ileal reservoir.. 39. 1997
Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate.. 39. 1997
Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation.. 39. 1997
Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy.. 39. 1997
Long-term regional control after radiation therapy and neck dissection for base of tongue carcinoma.. 38. 1997
Neon heavy charged particle radiotherapy of glioblastoma of the brain.. 38. 1997
Neuropsychological sequelae of medulloblastoma in adults.. 38. 1997
Variation in prostate position quantitation and implications for three-dimensional conformal treatment planning.. 38. 1997
A new technique for performing Syed-Neblett template interstitial implants for gynecologic malignancies using transrectal-ultrasound guidance.. 37. 1997
Measurement of patient positioning errors in three-dimensional conformal radiotherapy of the prostate.. 37. 1997
Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer.. 37. 1997
The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy.. 37. 1997
Gamma knife for glioma: selection factors and survival.. 36. 1996
High dose rate intracoronary radiation for inhibition of neointimal formation in the stented and balloon-injured porcine models of restenosis: angiographic, morphometric, and histopathologic analyses.. 36. 1996
Reirradiation of primary CNS tumors.. 36. 1996
The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin.. 36. 1996
Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children's Cancer Group.. 36. 1996
Medulloblastoma: long-term results for patients treated with definitive radiation therapy during the computed tomography era.. 36. 1996
Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.. 35. 1996
Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy.. 35. 1996
Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation.. 35. 1996
A comparison of intensity modulated conformal therapy with a conventional external beam stereotactic radiosurgery system for the treatment of single and multiple intracranial lesions.. 35. 1996
Radiosurgery for hemangioblastoma: results of a multiinstitutional experience.. 35. 1996
A method of incorporating organ motion uncertainties into three-dimensional conformal treatment plans.. 35. 1996
Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy.. 35. 1996
Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme.. 35. 1996
External beam radiation therapy and retinoblastoma: long-term results in the comparison of two techniques.. 35. 1996
The effect of setup uncertainties on the radiobiological advantage of fractionation in stereotaxic radiotherapy.. 34. 1996
Bromodeoxyuridine labeling index in glioblastoma multiforme: relation to radiation response, age, and survival.. 34. 1996
The influence of older age on breast cancer treatment decisions and outcome.. 34. 1996
The field-matching problem as it applies to the peacock three dimensional conformal system for intensity modulation.. 34. 1996
Treatment planning for carcinoma of the cervix: a patterns of care study report.. 34. 1996
Collision detection and avoidance during treatment planning.. 33. 1995
The effects of out-of-plane rotations on two dimensional portal image registration in conformal radiotherapy of the prostate.. 33. 1995
Three dimensional conformal treatment planning with multileaf collimators.. 33. 1995
The influence of radiotherapy on cosmetic outcome after breast conservative surgery.. 33. 1995
Effect of ocular implants of different materials on the dosimetry of external beam radiation therapy.. 32. 1995
Multileaf collimation versus alloy blocks: analysis of geometric accuracy.. 32. 1995
The relative biological effectiveness of I-125 and Pd-103.. 32. 1995
A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation.. 32. 1995
Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.. 32. 1995
Treatment planning structure and process in the United States: a "Patterns of Care" study.. 32. 1995
Episcleral iridium-192 wire therapy for choroidal melanomas.. 30. 1994
Initial clinical experience with computer-controlled conformal radiotherapy of the prostate using a 50-MeV medical microtron.. 30. 1994
Performance status after treatment for squamous cell cancer of the base of tongue--a comparison of primary radiation therapy versus primary surgery.. 30. 1994
Postoperative high dose-rate intravaginal brachytherapy combined with external irradiation for early stage endometrial cancer: a long-term follow-up.. 30. 1994
Short-term freedom from disease progression after I-125 prostate implantation.. 30. 1994
Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro.. 30. 1994
Effects of beam modifiers and immobilization devices on the dose in the build-up region.. 30. 1994
Prone position breast irradiation.. 30. 1994
Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast.. 30. 1994
Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation.. 29. 1994
Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia.. 29. 1994
Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy.. 29. 1994
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost.. 29. 1994
Trilateral retinoblastoma--incidence and outcome: a decade of experience.. 29. 1994
Breast cellulitis after conservative surgery and radiotherapy.. 29. 1994
Preclinical evaluation of the reliability of a 50 MeV racetrack microtron.. 28. 1994
Quantifying the effect of dose inhomogeneity in brachytherapy: application to permanent prostatic implant with 125I seeds.. 28. 1994
Treatment-related symptoms during the first year following transperineal 125I prostate implantation.. 28. 1994
Therapy monitoring in human and canine soft tissue sarcomas using magnetic resonance imaging and spectroscopy.. 28. 1994
Fractionated high-dose rate brachytherapy for intracranial gliomas.. 28. 1994
The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement.. 28. 1994
Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study.. 28. 1994
Ultrasound guided placement of transperineal prostatic afterloading catheters.. 28. 1994
The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group.. 27. 1993
Use of ultrasound to guide radiation boost planning following lumpectomy for carcinoma of the breast.. 27. 1993
Carcinoma of the cervix: predictive value of clinical and magnetic resonance (MR) imaging assessment of prognostic factors.. 27. 1993
Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells.. 27. 1993
Effect of set-up error on the dose across the junction of matching cranial-spinal fields in the treatment of medulloblastoma.. 27. 1993
Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk.. 27. 1993
The effect of setup uncertainties on the treatment of nasopharynx cancer.. 27. 1993
Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer.. 26. 1993
A CT-based evaluation method for permanent implants: application to prostate.. 26. 1993
Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.. 25. 1993
Short-term morbidity from CT-planned transperineal I-125 prostate implants.. 25. 1993
The use of a multi-leaf collimator for conformal radiotherapy of carcinomas of the prostate and nasopharynx.. 25. 1993
Lipid peroxidation does not appear to be a factor in late radiation injury of the cervical spinal cord of rats.. 25. 1993
Postoperative radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: impact of therapy on patients with positive surgical margins.. 25. 1993
A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer.. 24. 1992
Combined hyperthermia and irradiation in the treatment of superficial tumors: results of a prospective randomized trial of hyperthermia fractionation (1/wk vs 2/wk).. 24. 1992
Energy status in the murine FSaII and MCaIV tumors under aerobic and hypoxic conditions: an in-vivo and in-vitro analysis.. 23. 1992
High activity iodine-125 interstitial implant for gliomas.. 24. 1992
Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989.. 23. 1992
Induction chemotherapy for non-small cell lung cancer with clinically evident mediastinal node metastases: the role of postoperative radiotherapy.. 23. 1992
Infiltrating breast carcinoma in patients age 30 years and younger: long term outcome for life, relapse, and second primary tumors.. 23. 1992
Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience.. 24. 1992
Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model.. 23. 1992
Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer.. 22. 1992
Thermoradiotherapy of recurrent malignant brain tumors.. 23. 1992
Clinical implications of I-125 dosimetry of bone and bone-soft tissue interfaces.. 21. 1991
Twice daily thoracic irradiation for limited small cell lung cancer.. 21. 1991
Cobalt60 plaques in recurrent retinoblastoma.. 21. 1991
Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer.. 21. 1991
Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.. 21. 1991
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.. 21. 1991
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation.. 21. 1991
The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database.. 21. 1991
Treatment results of stereotactic interstitial brachytherapy for primary and metastatic brain tumors.. 21. 1991
CT-based optimized planning for transperineal prostate implant with customized template.. 21. 1991
Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy.. 21. 1991
Primary breast irradiation in large-breasted or heavy women: analysis of cosmetic outcome.. 21. 1991
Role of brachytherapy in recurrent extremity sarcoma in patients treated with prior surgery and irradiation.. 20. 1991
The role of uncertainty analysis in treatment planning.. 21. 1991
Three-dimensional photon treatment planning for Hodgkin's disease.. 21. 1991
Three-dimensional photon treatment planning for carcinoma of the nasopharynx.. 21. 1991
Three-dimensional photon treatment planning of the intact breast.. 21. 1991
Three-dimensional treatment planning considerations for prostate cancer.. 21. 1991
Three-dimensional treatment planning for lung cancer.. 21. 1991
Three-dimensional treatment planning for postoperative treatment of rectal carcinoma.. 21. 1991
A new device to stabilize templates for transperineal I-125 implants.. 20. 1991
Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx.. 20. 1991
Paraspinal tumors: techniques and results of brachytherapy.. 20. 1991
Cervical metastases from unknown primaries: radiotherapeutic management and appearance of subsequent primaries.. 19. 1990
Limb salvage in soft tissue sarcomas involving neurovascular structures using combined surgical resection and brachytherapy.. 19. 1990
Relationship of changes in pH and energy status to hypoxic cell fraction and hyperthermia sensitivity.. 18. 1990
Combined modality therapy of extrahepatic biliary system cancer.. 18. 1990
An interactive treatment planning system for ophthalmic plaque radiotherapy.. 18. 1990
A CT-based computerized treatment planning system for I-125 stereotactic brain implants.. 18. 1990
Glutathione depletion and cytotoxicity of buthionine sulphoximine and SR2508 in rodent and human cells.. 18. 1990
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.. 18. 1990
A phase I-II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies.. 17. 1989
Brachytherapy as part of the definitive management of squamous cancer of the base of tongue.. 17. 1989
Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens.. 17. 1989
Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas.. 17. 1989
The patients perception of her breast following radiation and limited surgery.. 17. 1989
Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease.. 17. 1989
Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation.. 17. 1989
Definitive irradiation for localized non-Hodgkin's lymphoma of breast.. 17. 1989
Charged particle radiotherapy for lesions encircling the brain stem or spinal cord.. 17. 1989
The use of lymphoscintigraphy in treatment planning of primary breast cancer.. 17. 1989
A new calculational method to assess the therapeutic potential of Auger electron emission.. 17. 1989
Computer assisted treatment planning for 125I ophthalmic plaque radiotherapy.. 17. 1989
Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.. 16. 1989
Postoperative radiotherapy of primary spinal cord tumors.. 16. 1989
Auger electron contribution to bromodeoxyuridine cellular radiosensitization.. 16. 1989
Charged particle irradiation of chordoma and chondrosarcoma of the base of skull and cervical spine: the Lawrence Berkeley Laboratory experience.. 15. 1988
Iridium-192 implants for primary breast cancer: experience with placement at the time of wide local excision.. 15. 1988
Radiation therapy for retinoblastoma: comparison of results with lens-sparing versus lateral beam techniques.. 15. 1988
A comprehensive three-dimensional radiation treatment planning system.. 15. 1988
Preliminary results of alternating combination chemotherapy (CT) and hyperfractionated radiotherapy (HART) in advanced rhabdomyosarcoma (RMS).. 15. 1988
Immunosuppression prior to marrow transplantation for sensitized aplastic anemia patients: comparison of TLI with TBI.. 14. 1988
Applicator for optimum cobalt-60 primary breast treatments.. 14. 1988
Improved survival of poor prognosis diffuse histiocytic (large cell) lymphoma managed with sequential induction chemotherapy, "boost" radiation therapy, and autologous bone marrow transplantation.. 14. 1988
Size dependent changes in tumor phosphate metabolism after radiation therapy as detected by 31P NMR spectroscopy.. 13. 1987
A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy.. 13. 1987
Limited resection for breast cancer: a study of inked specimen margins before radiotherapy.. 13. 1987
CT-assisted assessment of bladder and rectum dose in gynecological implants.. 13. 1987
Dose distributions of model 6702 I-125 seeds in water.. 13. 1987
Combined surgery and radiation in endometrial carcinoma: an analysis of prognostic factors.. 13. 1987
Is cranial radiation necessary for CNS prophylaxis in pediatric NHL?. 13. 1987
Megavoltage radiotherapy using water bolus in the treatment of Kaposi's sarcoma.. 12. 1986
Interstitial microwave hyperthermia in a canine brain model.. 12. 1986
A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation.. 12. 1986
Scatter dose summation for irregular fields: speed and accuracy study.. 12. 1986
Tumor size dependent changes in a murine fibrosarcoma: use of in vivo 31P NMR for non-invasive evaluation of tumor metabolic status.. 12. 1986
A non-looping afterloading technique for base of tongue implants: results in the first 20 patients.. 11. 1985
Detection of S-phase overreplication following chronic hypoxia using a monoclonal anti-BrdUrd.. 11. 1985
Precision, high dose radiotherapy. II. Helium ion treatment of tumors adjacent to critical central nervous system structures.. 11. 1985
Relative biological effectiveness of 125I sources in a murine brachytherapy model.. 10. 1984
Cell killing, radiosensitization and cell cycle redistribution induced by chronic hypoxia.. 10. 1984
The effect of combination treatment with cis-platinum and low dose rate 125I radiation in a murine brachytherapy model.. 10. 1984
Radiation therapy in adenoid-cystic carcinoma.. 10. 1984
Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants.. 9. 1983
Physical dosimetry of 125I seeds of a new design for interstitial implant.. 9. 1983
Presumptive downstaging from preoperative irradiation for bladder cancer as determined by flow cytometry: preliminary report.. 9. 1983
The effect of postoperative radiotherapy on the feasibility of optimal dose adjuvant CMF chemotherapy in stage II breast carcinoma.. 9. 1983
Current concepts in cancer: ovary--treatment for stages III and IV. The multimodal approach to the treatment of stage III ovarian carcinoma.. 8. 1982
Radiosensitization of the RIF-1 murine flank tumor by desmethylmisonidazole (Ro 05 9963) during interstitial brachytherapy.. 8. 1982
Radiation myelopathy in the rat: an interpretation of dose effect relationships.. 7. 1981
The comparison of total body irradiation vs chlorambucil and prednisone for remission induction of active chronic lymphocytic leukemia: an ECOG study. Part I: total body irradiation-response and toxicity.. 7. 1981
Permanent and removable implants for the brachytherapy of brain tumors.. 7. 1981
Hyperfractionated total body irradiation for bone marrow transplantation: I. Early results in leukemia patients.. 7. 1981
Dosimetry, field shaping and other considerations for intra-operative electron therapy.. 7. 1981
Selective modification of the X ray survival response of two mouse mammary adenocarcinoma sublines by N,N-dimethylformamide.. 7. 1981
Activity uniformity of Ir-192 seeds.. 7. 1981
Follow-up neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy.. 7. 1981
The treatment of intractable rheumatoid arthritis with lymphoid irradiation.. 7. 1981
The use of total lymphoid irradiation (TLI) as immunosuppressive therapy for organ allotransplantation and autoimmune diseases.. 7. 1981
Half-body and local chest irradiation as consolidation following response to standard induction chemotherapy for disseminated small cell lung cancer: an Eastern Cooperative Oncology Group pilot report.. 6. 1980
Nasopharyngeal carcinoma in children review of 16 cases.. 6. 1980
The rationale for curative radiotherapy in mycosis fungoides.. 2. 1977
"Total" therapy for oat cell carcinoma of the lung.. 2. 1977
Successful chemotherapy of advanced non-Hodgkin's lymphoma after relapse following total body irradiation.. 2. 1977
The rationale for curative radiotherapy for ovarian carcinoma.. 1. 1975
In Regard to Rahimi et al.. 99. 2017
In reply to Dixon and Thomas.. 89. 2014
Consensus statement: APBI from ASTRO (Int J Radiat Oncol Biol Phys 2009;74:987-1001).. 76. 2010
Prone-breast radiotherapy: too early for conclusions: in regard to Chino et Al. (Int j radiat oncol biol phys 2008;70:916-920).. 72. 2008
External beam partial-breast radiotherapy: crucial differences between NYU 00-23 and RTOG 0319: in regard to Vicini et al. (Int J Radiat Oncol Biol Phys 2005;63:1531-1537).. 66. 2006
In regard to Kao et al.: concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials (Int J Radiat Oncol Biol Phys 2005;61:1045-1053).. 63. 2005
Biologic comparisons of partial breast irradiation schedules: In regard to Rosenstein et al. (Int J Radiat Oncol Biol Phys 2004;60:1391-1404).. 62. 2005
Chasing your dural tail: Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas: In regard to DiBiase et al. (Int J Radiat Oncol Biol Phys 2004;60:1515-1519).. 62. 2005
Staging of advanced cervical cancer.. 62. 2005
CTV margins in prostate cancer irradiation. In regard to Teh et al.: IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease (Int J Radiat Oncol Biol Phys 2003;56:184-191).. 59. 2004
In regard to Huang et al.: Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. IJROBP 2002;52:599-605.. 55. 2003
Regarding Zelefsky, Leibel, Gaudin, et al., IJROBP 1998;41:491-500.. 43. 1999
In response to Drs. Goitein and Niemierko.. 38. 1997
Re: Lo et al. IJROBP 34(5):1113-1119; 1996.. 36. 1996
Clinical realization of 3D conformal intensity modulated radiotherapy: regarding Bortfeld et al., IJROBP 30:899-908; 1994.. 32. 1995
Further characterization of postradiotherapy cellulitis and efforts at prevention.. 31. 1995
Response to editorial by Dr. Maruyama.. 27. 1993
In regard to Yamamoto et al. 2012
What Would I Want Done for My Mother? 2019
In Reply to Minhas and Tran. 2019
Precision Medicine-Targeted Therapy. 2018
In Reply to Pareek. 2017
Response to "Stereotactic ablative radiotherapy in the framework of classical radiobiology: response to Drs. Brown, Diehn, and Loo." (Int J Radiat Oncol Biol Phys 2011;79:1599-1600) and "Influence of tumor hypoxia on stereotactic ablative radiotherapy (SABR): response to Drs. Mayer and Timmerman." (Int J Radiation Oncol Biol Phys 2011;78:1600). 2011
Hippocampal-sparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy: in regard to Gondi v, et al. (Int j radiat oncol biol phys 2010;78:1244-1252). 2011
Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. 2003
Proceedings of the American Radium Society's 62nd annual meeting 28 April-1 May 1980. 1979
In Memoriam: David A. Larson, MD, PhD, FASTRO (December 17, 1940 - November 4, 2022).. 118. 2024
⁶⁸Ga-DOTATATE PET: The Future of Meningioma Treatment.. 113. 2022
Prostate SBRT Dose Escalation (9 Gy × 5, 13.3 Gy × 3, 24 Gy × 1): Are We Making Progress?. 111. 2021
Future of Radiation and Immunotherapy.. 108. 2020
Challenging the Norm: What Level of Evidence Is Necessary to Adopt Postprostatectomy Hypofractionated Radiation Therapy?. 107. 2020
Radiation Therapy in Gabon: Multi-Institutional Collaboration as a Paradigm for Growth in the African Radiation Oncology Sector.. 106. 2020
The ASTRO Research Portfolio: Where Do We Go From Here?. 103. 2019
Optimizing Dose Per Fraction: A New Chapter in the Story of the Abscopal Effect?. 99. 2017
The Pace of Progress in Radiation and Immunotherapy.. 95. 2016
Radiation therapy and immunotherapy: growing pains.. 91. 2015
Improved long-term outcomes with IMRT: is it better technology or better physics?. 87. 2013
Radiation therapy to convert the tumor into an in situ vaccine.. 84. 2012
Timing of lethality from gastrointestinal syndrome in mice revisited.. 73. 2009
High-tech will improve radiotherapy of NSCLC: a hypothesis waiting to be validated.. 60. 2004
EUD but not QED.. 52. 2002
Radiation therapy for stage III follicular lymphoma-often ignored, but still effective.. 49. 2001
Do not miss a second (and possibly last) chance to cure Hodgkin's disease.. 39. 1997
Magnetic resonance tumor volumetry in cervical cancer.. 35. 1996
Sequencing: one big tree in the forest on breast cancer management.. 35. 1996
New wine in an old bottle? Dose escalation under dose-volume constraints: a model of conformal therapy of the prostate.. 35. 1996
Improving local control in breast conserving therapy: to clip or not to clip?. 34. 1996
Integrating radiotherapy into bone marrow transplantation programs for Hodgkin's disease.. 33. 1995
When becometh less more?. 33. 1995
Understanding radiation damage in late effect normal tissues: learning to negotiate the dose-volume-complication terrain or waiting for Godot?. 31. 1995
Breast conservation for ductal carcinoma in situ: what is the risk?. 30. 1994
Does the "peacock" have anything to do with radiotherapy?. 29. 1994
Editorial on "The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix".. 29. 1994
Refining the predictive power of the prostate-specific antigen.. 27. 1993
Conventional external beam radiation therapy for prostatic cancer: where do we go from here?. 26. 1993
Is local failure a cause of or a marker for metastatic dissemination in carcinoma of the uterine cervix?. 24. 1992
Radiation tolerance and the new biology: growth factor involvement in radiation injury to the lung.. 24. 1992
Radiation Therapy and the In Situ Vaccination Approach. 2020
Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. 2020
Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. 2020
Enhancing Career Paths for Tomorrow's Radiation Oncologists. 2019
Smart Radiation Therapy Biomaterials. 2016
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. 2014
Rhabdomyosarcoma arising in a previously irradiated field: an analysis of 43 patients. 2012
The next chapter in immunotherapy and radiation combination therapy - cancer-specific perspectives. 2024
An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer. 2021
Radium-223 in the treatment of osteoblastic metastases: a critical clinical review. 2015
A comparison of survival of patients treated for AIDS-related central nervous system lymphoma with and without tissue diagnosis. 1996

VIVO Weill Cornell Medical College

International journal of radiation oncology, biology, physics Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)